ALZAMEND NEURO, INC. Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ALZAMEND NEURO, INC. (ALZN) reported Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $9.86 million for the 9-month period ending 2022-01-31, per its 10-Q filed 2022-03-15.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2022-03-15
- ALZAMEND NEURO, INC. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-07-31 was $13.69M.
- ALZAMEND NEURO, INC. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-07-31 was -$27.17K.
- ALZAMEND NEURO, INC. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $1.84M, a 3757.01% increase from fiscal 2020.
- ALZAMEND NEURO, INC. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $47.68K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-01-31 | $9.86M 10-Q · filed 2022-03-15 | |||
| 2021-10-31 | $11.64M 10-Q · filed 2021-12-13 | |||
| 2021-07-31 | $13.69M 10-Q · filed 2021-09-13 | |||
| 2021-04-30 | $1.84M 10-K · filed 2021-07-29 | |||
| 2021-01-31 | -$49.55K 10-Q · filed 2022-03-15 | |||
| 2020-10-31 | -$84.42K 10-Q · filed 2021-12-13 | |||
| 2020-07-31 | -$27.17K 10-Q · filed 2021-09-13 | |||
| 2020-04-30 | $47.68K 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |